What is tirzepatide? The dual-action weight loss medication, explained

What is tirzepatide?

Tirzepatide is the active ingredient in a once-weekly injection developed by Eli Lilly for type 2 diabetes and for chronic weight management. It belongs to a group of medicines that copy natural gut hormones the body releases after eating.

It is given as a subcutaneous injection, meaning into the fat layer just under the skin, usually in the stomach, thigh or upper arm. It is a Schedule 4 medicine in South Africa, so it always requires a doctor's assessment and authorisation, and it is dispensed by licensed pharmacies only.

Tirzepatide sits within the wider family of GLP-1 weight-loss treatment, but it is not a pure GLP-1 medicine. The next section explains why that distinction matters.

What does dual-action mean?

Most weight-loss injections work on one receptor, GLP-1. Tirzepatide works on two: GIP and GLP-1. Both are hormones your gut releases after a meal, and both influence appetite, insulin and how full you feel.

GLP-1 slows stomach emptying, curbs appetite and prompts the pancreas to release insulin when blood sugar rises. GIP adds a second signal that also affects insulin and appetite regulation, and may help the body process fat and sugar more efficiently. Targeting both at once is why tirzepatide is described as a dual agonist or a twincretin.

For a direct comparison of the two mechanisms and their trial results, see semaglutide vs tirzepatide.

What is tirzepatide sold as in South Africa?

In South Africa, tirzepatide is sold as Mounjaro, distributed by Aspen Pharmacare in partnership with Eli Lilly. It comes as the Mounjaro KwikPen, a pre-filled multi-dose pen that holds four weekly doses. You attach a fresh pen needle for each dose; pharmacies sell the needles separately if they are not included.

Aspen launched Mounjaro here in December 2024, initially for type 2 diabetes and supplied at first in single-dose vials. The KwikPen has since replaced those vials, so the pre-filled pen is what South African pharmacies now stock. In October 2025, SAHPRA, the South African Health Products Regulatory Authority, approved a second indication: chronic weight management in adults.

For the full local picture, including who it is registered for, read is Mounjaro available in South Africa.

Is Zepbound available in South Africa?

No. Zepbound is not registered with SAHPRA, so South African pharmacies do not stock it. Zepbound is Eli Lilly's international brand of tirzepatide for weight management, used in markets such as the United States. In South Africa the same molecule is registered as Mounjaro, and that registration has covered chronic weight management since October 2025.

In practice, a search for Zepbound in South Africa ends at the same active ingredient under a different name. The route is identical too: a doctor's assessment, then dispensing by a licensed pharmacy.

Treat any website offering to ship Zepbound to South African buyers with caution. It is not dispensing a SAHPRA-registered product, and the packaging gives you no way to confirm what the pen contains.

How well does tirzepatide work for weight loss?

The main evidence is SURMOUNT-1, a 72-week trial of 2,539 adults with obesity or overweight, published in the New England Journal of Medicine. Average weight loss was 15% of body weight on the 5 mg dose, 19.5% on 10 mg and 20.9% on 15 mg, compared with about 2.4% on placebo. Individual results vary.

Responder rates followed the same pattern. Around nine in ten participants on the higher doses lost at least 5% of their body weight, against roughly a quarter of the placebo group. Individual results vary.

A later head-to-head trial, SURMOUNT-5, compared tirzepatide with semaglutide 2.4 mg over 72 weeks. Tirzepatide produced greater average weight loss: 20.2% against 13.7%. Individual results vary. In every trial, participants also followed a reduced-calorie diet and an activity plan, so the medicine supported those changes rather than replacing them. Whether those averages make tirzepatide the better fit for you is decided by a doctor on assessment.

What did the SURPASS trials show in type 2 diabetes?

SURPASS is the trial programme that tested tirzepatide in type 2 diabetes, and it showed large improvements in blood sugar control alongside weight loss. In SURPASS-2, a 40-week trial of 1,879 adults on metformin, average HbA1c fell by 2.0 to 2.3 percentage points depending on the dose. Individual results vary.

The comparator was semaglutide 1 mg, the diabetes dose of that molecule at the time, which lowered HbA1c by 1.86 percentage points. Weight moved the same way: participants on tirzepatide 15 mg lost 12.4 kg on average, against 6.2 kg on semaglutide 1 mg. Individual results vary.

These diabetes results are why Mounjaro launched in South Africa for type 2 diabetes first, with the weight management registration following in 2025. They also sit behind the caution about low blood sugar for anyone who takes insulin or sulfonylureas, covered under side effects below. As with every comparison in this class, the right molecule for a specific patient is decided by a doctor on assessment.

How is tirzepatide dosed?

Tirzepatide is injected once a week, on the same day each week. Treatment starts low and steps up gradually so the body can adjust and to limit side effects.

Your doctor sets the pace of increases based on how you respond and tolerate each step. Not everyone reaches the maximum dose; many people settle at a middle dose that balances results and side effects. The step-by-step schedule is covered in our Mounjaro dosage guide.

A practical note on the KwikPen: it must be kept in a fridge at 2 to 8 degrees Celsius, so plan collection and travel around that. Do not switch between pen strengths or double up doses on your own if a strength is out of stock; speak to your doctor first, because the schedule can usually be adjusted safely.

Is there a tirzepatide 30 mg pen?

Not a registered one. The registered tirzepatide strengths in South Africa run from 2.5 mg to 15 mg per weekly dose, supplied in the Mounjaro KwikPen. A pen or vial labelled tirzepatide 30 mg is not one of the registered presentations, and it usually signals a compounded or so-called research-grade product.

These 30 mg and 60 mg products are sold through websites and social media as peptides, often with a research-use label that supposedly shifts responsibility to the buyer. SAHPRA has not evaluated them for safety, quality or efficacy, and their contents and sterility are unverified. Enforcement is active: a joint SAHPRA and South African Pharmacy Council inspection in May 2026 emptied a Pretoria compounding pharmacy of its unregistered GIP and GLP-1 injectable stock.

The registered product reaches you one way: a licensed pharmacy dispenses it, cold from the fridge, in sealed Eli Lilly packaging with a batch number and expiry date, against a doctor-confirmed treatment plan. Suspicious sellers can be reported to SAHPRA's 24-hour hotline on 0800 204 307. The legal and safety questions around online sellers are unpacked in what is legal and safe when these medicines are sold online.

What are the side effects of tirzepatide?

The most common side effects are digestive: nausea, diarrhoea, constipation, vomiting and indigestion. They are usually mild to moderate, tend to appear when the dose increases, and often settle as the body adjusts. Slower dose increases, smaller meals and staying hydrated all help.

Less common effects range from minor to serious. Injection-site redness or itching usually passes, and rotating sites helps. Gallbladder problems occur in a small number of people, typically signalled by pain under the right ribs after meals. Severe, persistent stomach pain can be a sign of pancreatitis: seek medical care immediately.

Because tirzepatide can lower blood sugar, people who also take insulin or sulfonylureas need closer monitoring. A doctor reviews your medicines and medical history before treatment, then follows up as the dose changes.

Who should not use tirzepatide?

Tirzepatide should not be used in pregnancy or while breastfeeding, or by anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome. It is also not registered for people under 18, for cosmetic weight loss, or for people already in a healthy weight range.

A history of pancreatitis needs careful discussion with a doctor before treatment is considered, and severe gut or gallbladder disease belongs in that conversation too.

The registered weight management use covers adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or sleep apnoea. BMI is a screening number rather than a full picture: a doctor also weighs your medical history, current medicines and previous weight loss attempts. How doctors assess obesity as a medical condition is a separate guide.

Is tirzepatide available in South Africa, and what does it cost?

Yes. Tirzepatide is available in South Africa as the Mounjaro KwikPen, stocked by major pharmacy groups including Dischem and Clicks, by independent pharmacies and by licensed courier pharmacies that deliver in cold-chain packaging. Availability of individual strengths fluctuates with demand, so phone the branch before you travel.

Published South African pharmacy prices in 2026 range from roughly R3,600 to R8,200 per KwikPen depending on the strength, and one pen covers about a month. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy. A realistic monthly budget also includes doctor consultations, any baseline blood tests and follow-up reviews.

The medicine price itself is regulated. South Africa's Single Exit Price system gives each pack one national price, so pharmacies differ mainly in the dispensing fee added on top. The full breakdown by strength, and how that pricing system works, is in how much Mounjaro costs in South Africa.

Does medical aid cover tirzepatide?

Usually not for weight management. Obesity is not a Prescribed Minimum Benefit condition, so most schemes exclude weight loss medicine from standard cover, and most people pay out of pocket. Some schemes do fund tirzepatide for type 2 diabetes under chronic benefits.

Check your medical savings account too: even when a scheme declines the medicine as a benefit, many members can pay for it from their savings account at the till. Scheme rules also change from year to year, so ask your scheme for its current position in writing.

How schemes handle weight loss treatment more broadly is explained on our medical aid page.

How do you start treatment in South Africa?

Because tirzepatide is a Schedule 4 medicine, the route is the same everywhere: a doctor assesses your health, weight history and goals, and where treatment is clinically appropriate, confirms a treatment plan. A licensed pharmacy then dispenses the medicine. No legitimate pharmacy dispenses it without a doctor's authorisation.

The assessment can happen at a GP practice or through a doctor-led telehealth service, and it checks blood pressure, medical history, current medicines and contraindications first. Follow-up reviews matter just as much, because doses change over the first few months and side effects need managing along the way. Tirzepatide also works best as part of a wider plan: it curbs appetite, but the diet and activity changes it supports are what make the results last.

Frequently asked questions